[go: up one dir, main page]

DE102004016437A1 - Verfahren zur Erkennung von Signaturen in komplexen Genexpressionsprofilen - Google Patents

Verfahren zur Erkennung von Signaturen in komplexen Genexpressionsprofilen Download PDF

Info

Publication number
DE102004016437A1
DE102004016437A1 DE102004016437A DE102004016437A DE102004016437A1 DE 102004016437 A1 DE102004016437 A1 DE 102004016437A1 DE 102004016437 A DE102004016437 A DE 102004016437A DE 102004016437 A DE102004016437 A DE 102004016437A DE 102004016437 A1 DE102004016437 A1 DE 102004016437A1
Authority
DE
Germany
Prior art keywords
expression profile
expression profiles
complex
determining
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE102004016437A
Other languages
English (en)
Inventor
Thomas Haeupl
Joachim Gruen
Andreas Radbruch
Gerd-Ruediger Burmester
Christian Kaps
Andreas Gruetzkau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OLIGENE GmbH
Original Assignee
OLIGENE GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OLIGENE GmbH filed Critical OLIGENE GmbH
Priority to DE102004016437A priority Critical patent/DE102004016437A1/de
Priority to EP05716523A priority patent/EP1733050A2/de
Priority to PCT/EP2005/003520 priority patent/WO2005095644A2/de
Priority to US11/547,040 priority patent/US20080108509A1/en
Publication of DE102004016437A1 publication Critical patent/DE102004016437A1/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Die vorliegende Erfindung betrifft ein Verfahren zur Erkennung von Signaturen in komplexen Genexpressionsprofilen, das die Schritte umfaßt von: a) zur Verfügung stellen einer zu untersuchenden biologischen Probe, b) zur Verfügung stellen mindestens eines geeigneten Expressionsprofils, wobei das mindestens eine Expressionsprofil einen oder mehrere Marker umfaßt, die ausschließlich für das Expressionsprofil typisch sind, c) Bestimmen des komplexen Expressionsprofils der biologischen Probe, d) Bestimmen der quantitativen zellulären Zusammensetzung der biologischen Probe mittels der in den Schritten b) und c) bestimmten Expressionsprofile. Weiterhin kann das erfindungsgemäße Verfahren die Schritte von e) Berechnung eines virtuellen Signals, das aufgrund der bestimmten Zusammensetzung der Expressionsprofile erwartet wird, f) Berechnung der Differenz aus dem tatsächlichen gemessenen komplexen Expressionsprofil und dem virtuellen Signal und g) Bestimmen der quantitativen Zusammensetzung des komplexen Expressionsprofils auf Basis der ermittelten Differenzen umfassen. Die vorliegende Erfindung betrifft weiterhin die Anwendung des erfindungsgemäßen Verfahrens in der Diagnose, Prognose und/oder Verfolgung einer Erkrankung. Schließlich werden entsprechende Computersysteme, Computerprogramme, computerlesbare Datenträgermedien und Laborroboter oder Auswertegeräte für molekulare Nachweismethoden offenbart.
DE102004016437A 2004-04-04 2004-04-04 Verfahren zur Erkennung von Signaturen in komplexen Genexpressionsprofilen Ceased DE102004016437A1 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
DE102004016437A DE102004016437A1 (de) 2004-04-04 2004-04-04 Verfahren zur Erkennung von Signaturen in komplexen Genexpressionsprofilen
EP05716523A EP1733050A2 (de) 2004-04-04 2005-04-04 Verfahren zur erkennung von signaturen in komplexen genexpressionsprofilen
PCT/EP2005/003520 WO2005095644A2 (de) 2004-04-04 2005-04-04 Verfahren zur erkennung von signaturen in komplexen genexpressionsprofilen
US11/547,040 US20080108509A1 (en) 2004-04-04 2005-04-04 Process for Recognizing Signatures in Complex Gene Expression Profiles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004016437A DE102004016437A1 (de) 2004-04-04 2004-04-04 Verfahren zur Erkennung von Signaturen in komplexen Genexpressionsprofilen

Publications (1)

Publication Number Publication Date
DE102004016437A1 true DE102004016437A1 (de) 2005-10-20

Family

ID=34979107

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102004016437A Ceased DE102004016437A1 (de) 2004-04-04 2004-04-04 Verfahren zur Erkennung von Signaturen in komplexen Genexpressionsprofilen

Country Status (4)

Country Link
US (1) US20080108509A1 (de)
EP (1) EP1733050A2 (de)
DE (1) DE102004016437A1 (de)
WO (1) WO2005095644A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603585A2 (de) 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotid kodierend für eine neue humane g-proteingekoppelte rezeptor-variante von hm74, hgprbmy74
WO2008066878A2 (en) * 2006-11-29 2008-06-05 University Of Vermont And State Agricultural College Methods and products for diagnosing cancer
WO2008134020A1 (en) 2007-04-26 2008-11-06 University Of Vermont And State Agricultural College Ccl18 and ccl3 methods and compositions for detecting and treating cancer
GB0722582D0 (en) * 2007-11-16 2007-12-27 Secr Defence Early detection of sepsis
CA2878025C (en) * 2008-01-18 2018-12-11 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
WO2010032816A1 (ja) * 2008-09-19 2010-03-25 小野薬品工業株式会社 新規リゾホスファチジルセリン受容体
US8691510B2 (en) 2008-11-07 2014-04-08 Sequenta, Inc. Sequence analysis of complex amplicons
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US8236503B2 (en) 2008-11-07 2012-08-07 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
HUE029424T2 (en) 2009-01-15 2017-02-28 Adaptive Biotechnologies Corp Adaptive immunity profiling and a method for producing monoclonal antibodies
EP2435580A2 (de) * 2009-05-29 2012-04-04 The Regents of the University of California Mit toleranz bei transplantatempfängern assoziierte b-zellen-signatur
EP3409792B1 (de) 2009-06-25 2023-09-20 Fred Hutchinson Cancer Center Verfahren zur messung der adaptiven immunität
WO2011028945A1 (en) * 2009-09-03 2011-03-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
US9043160B1 (en) 2009-11-09 2015-05-26 Sequenta, Inc. Method of determining clonotypes and clonotype profiles
EP2385134A1 (de) * 2010-05-07 2011-11-09 Ludwig-Maximilians-Universität München Risikoprognoseverfahren für chronische lymphatische Leukämie
CA2806296A1 (en) * 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting kidney-associated diseases or conditions
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
CA2806293A1 (en) * 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
CA2853088C (en) 2011-10-21 2018-03-13 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
CA2858070C (en) 2011-12-09 2018-07-10 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
ES2662128T3 (es) 2012-03-05 2018-04-05 Adaptive Biotechnologies Corporation Determinación de cadenas de receptor inmunitario emparejadas a partir de la frecuencia de subunidades coincidentes
US9150905B2 (en) 2012-05-08 2015-10-06 Adaptive Biotechnologies Corporation Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions
JP2015528912A (ja) * 2012-07-23 2015-10-01 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 強皮症の診断方法
EP2904111B1 (de) 2012-10-01 2017-12-06 Adaptive Biotechnologies Corporation Immunkompetenzbeurteilung durch adaptive immunrezeptordiversität und klonalitätscharakterisierung
EP2965077B1 (de) 2013-03-09 2022-07-13 Harry Stylli Verfahren zur krebserkennung
CA2904658C (en) * 2013-04-19 2023-10-17 Epiontis Gmbh Method for identifying the quantitative cellular composition in a biological sample
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
ES2741740T3 (es) 2014-03-05 2020-02-12 Adaptive Biotechnologies Corp Métodos que usan moléculas sintéticas que contienen segmentos de nucleótidos aleatorios
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
ES2777529T3 (es) 2014-04-17 2020-08-05 Adaptive Biotechnologies Corp Cuantificación de genomas de células inmunitarias adaptativas en una mezcla compleja de células
US10392663B2 (en) 2014-10-29 2019-08-27 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from a large number of samples
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
EP3224384A4 (de) 2014-11-25 2018-04-18 Adaptive Biotechnologies Corp. Charakterisierung von adaptiver immunreaktion auf impfungen oder infektionen unter verwendung von immunrepertoiresequenzierung
ES3002665T3 (en) 2015-02-24 2025-03-07 Adaptive Biotechnologies Corp Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing
EP3277294B1 (de) 2015-04-01 2024-05-15 Adaptive Biotechnologies Corp. Verfahren zur identifizierung von menschlichen kompatiblen t-zell-rezeptoren spezifisch für ein antigen-ziel
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
EP4526473A2 (de) * 2022-05-20 2025-03-26 Novigenix SA Biomarker für kolorektale neoplasie

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072065A2 (en) * 2002-02-28 2003-09-04 Iconix Pharmaceuticals, Inc. Drug signatures
WO2003083141A1 (en) * 2002-03-29 2003-10-09 Arcturus Engineering, Inc. Interpreting cytological specimens via molecular histological signatures
WO2004005882A2 (en) * 2001-06-18 2004-01-15 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (mphts)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104394A1 (en) * 2001-12-03 2003-06-05 Xudong Dai Method and system for gene expression profiling analysis utilizing frequency domain transformation
DE10159404A1 (de) * 2001-12-04 2003-06-26 Arevia Gmbh Verfahren zur Analyse von Gewebeproben
WO2005028677A2 (en) * 2003-05-07 2005-03-31 Agilent Technologies, Inc. Systems and methods for determining cell type composition of mixed cell populations using gene expression signatures

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005882A2 (en) * 2001-06-18 2004-01-15 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (mphts)
WO2003072065A2 (en) * 2002-02-28 2003-09-04 Iconix Pharmaceuticals, Inc. Drug signatures
WO2003083141A1 (en) * 2002-03-29 2003-10-09 Arcturus Engineering, Inc. Interpreting cytological specimens via molecular histological signatures

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KIM, S. u.a.: Identification of combination gene sets for glioma classification. Mol. Cancer Ther. (2002) 1 (13) 1229-36 *
TÜRECI, Ö. u.a.: Computational dissection of tissue contamination for identification of colon cancer-specific expression profiles. FASEB J. (2003) 17 (3) 376-85 *
VENET, D. u.a.: Separation of samples into their constituents using gene expression data. Bioinfor-matics (2001) 17 (Suppl. 1) 279-87 *

Also Published As

Publication number Publication date
EP1733050A2 (de) 2006-12-20
WO2005095644A2 (de) 2005-10-13
WO2005095644A3 (de) 2006-04-13
US20080108509A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
DE102004016437A1 (de) Verfahren zur Erkennung von Signaturen in komplexen Genexpressionsprofilen
Malekjafarian et al. A review of mobile sensing of bridges using moving vehicles: Progress to date, challenges and future trends
Staals et al. Total MRI load of cerebral small vessel disease and cognitive ability in older people
Agbor-Enoh et al. Applying rigor and reproducibility standards to assay donor-derived cell-free DNA as a non-invasive method for detection of acute rejection and graft injury after heart transplantation
EP2113437A3 (de) Verfahren zur Bestimmung von freien Bereichen in der, insbesondere für die Fahrzeugführung relevanten Umgebung eines Kraftfahrzeugs
WO2011079938A3 (en) System and method for determining the concentration of an analyte in a sample fluid
EP2078945A3 (de) Verfahren und Vorrichtung zur Analyse und Bewertung von Messdaten eines Messsystems
EP2770328A3 (de) Verfahren zur Diagnose von Bauchspeicheldrüsenkrebs
EP2500475A3 (de) Verfahren und Vorrichtung zum selbsttätigen Spülen von Leitungen
JP2010525332A5 (de)
BR112012019542A2 (pt) "método para avaliar o estado renal em um indivíduo, medição de um ou mais biomarcadores, e, kit"
AT514311A5 (de) Verfahren zum Identifizieren einer Teilmenge von Polynucleotiden aus einer dem Humangenom entsprechenden Ausgangsmenge von Polynucleotiden zur in vitro Bestimmung eines Schweregrads der Wirtsantwort eines Patienten
WO2006126008A3 (en) Improved immunoassay methods
EP1215495A3 (de) Verfahren zur Erhöhung der klinischen Spezifität bei der Detektion von Tumoren und ihren Vorstufen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern
Franco et al. Can a quantitative means be used to predict flow patterns: agreement between visual inspection vs. flow index derived flow patterns
De Carvalho et al. Sensitivity of MUP parameters in detecting change in early ALS
EP1215475A3 (de) Verfahren zum Überprüfen der Bremse eines Elektromotors
Macleod et al. Co-morbidity burden in Parkinson’s disease: comparison with controls and its influence on prognosis
CN119614730B (zh) 一种与帕金森综合征相关的肠道菌群标志物及其应用
CN103293250B (zh) 糖尿病肾病诊断试剂盒及其应用
WO2021170441A1 (de) Verfahren und vorrichtung zur durchführung eines qpcr-verfahrens
NZ592819A (en) Thyroid analyte detection and measurement
EP1715333A3 (de) Verfahren zur Signalauslesung an einem gassensitiven Feldeffekttransistor
ATE550668T1 (de) Verfahren zur identifizierung von patienten mit erhöhtem risiko für ein unerwünschtes herz- kreislauf-ereignis
DE10346863A1 (de) On-Board-Kontrolle für Analyseelemente

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8131 Rejection